Lit Review: Angiotensin II, Sigh Ventilation, & PPIs

We analyze clinical strategies and pharmaceutical outcomes within intensive care environments. One study concludes that using Angiotensin II to treat severe, non-responsive shock does not lower patient mortality rates compared to traditional therapies. Another trial explores sigh ventilation for trauma patients, finding that while it did not significantly increase time off mechanical support, it appeared safe and potentially linked to better survival. A third investigation highlights the dangers of failing to stop proton pump inhibitors after hospital discharge, noting a higher risk of serious medical complications and death. Collectively, these articles emphasize the importance of data-driven protocols to improve the safety and recovery of critically ill patients.

 

 

DISCLAIMER
The Critical Edge is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease, nor does it substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider—always seek in-person evaluation and care from your physician or trauma team for any health concerns.

 

 

 

Comprehensive Study Guide: Advancements and Outcomes in Critical Care Interventions

This study guide provides a detailed synthesis of recent research concerning three distinct critical care interventions: the use of Angiotensin II for refractory shock, the implementation of sigh ventilation for trauma patients, and the clinical impacts of prolonged proton pump inhibitor (PPI) use following intensive care.

Section 1: Angiotensin II for the Treatment of Refractory Shock

Overview of Distributive Shock

Distributive shock is a frequent etiology in the intensive care unit (ICU). It is characterized by systemic vasodilation, leaky capillaries, and inadequate tissue perfusion, which collectively result in reduced blood flow to vital organs. Angiotensin II (AT2 or ATII) is a vasoconstrictor recently utilized to address this condition by increasing blood pressure through direct renal vasoconstriction and the promotion of fluid retention.

The Smith et al. Study (2023)

A matched analysis was conducted at the University of Michigan to evaluate whether ATII is associated with improved clinical outcomes in adult patients experiencing severe shock.

• Study Design: This was a retrospective, single-institution matched analysis using the DataDirect database. It compared 271 patients who received ATII to a control group of 542 patients who received equivalent doses of traditional vasopressors (norepinephrine, phenylephrine, vasopressin, or dopamine).
• Patient Characteristics: Patients in the ATII group generally presented with higher severity of illness at enrollment, including higher Sequential Organ Failure Assessment (SOFA) scores, lower mean arterial pressure (MAP), higher lactic acid levels, and higher rates of chronic illness and septic shock. They were also more likely to require mechanical ventilation and renal replacement therapy (RRT) at the start.
• Primary Outcomes: The study focused on mortality at 30 and 90 days. After adjusting for baseline characteristics, mortality rates were found to be similar between groups:
  • 30-day Mortality: 60% for ATII vs. 56% for controls (p=0.292).
  • 90-day Mortality: 65% for ATII vs. 63% for controls (p=0.440).
• Secondary Outcomes: ATII use showed no significant association with improved organ dysfunction. There were no meaningful differences in the new onset of renal replacement therapy, duration of mechanical ventilation, or the rate of thrombotic events.

Comparative Analysis and Limitations

The findings align with the ATHOS-3 trial, which also failed to find a primary mortality benefit for ATII. However, a subgroup analysis in ATHOS-3 suggested a benefit for patients already receiving renal replacement therapy. A key difference between the studies is that ATHOS-3 maintained ATII dosing while weaning other pressors, whereas the Smith et al. study examined ATII primarily as a "salvage therapy" for refractory hypotension.

The retrospective, single-center nature of the Smith study limits its generalizability. The researchers noted that using ATII as a last-resort salvage therapy might limit its potential clinical benefits, suggesting that future research should investigate its use as a first- or second-line therapy.

--------------------------------------------------------------------------------

Section 2: Sigh Ventilation in Trauma Patients

Physiological Rationale

Patients on mechanical ventilation typically receive a constant tidal volume. "Sigh breaths"—occasional maximal breaths—are theorized to stimulate surfactant secretion, maintain alveolar recruitment for gas exchange, and prevent alveolar collapse. These functions may potentially reduce ventilator-induced lung injury (VILI).

The SiVent Randomized Clinical Trial

The SiVent trial was a pragmatic, parallel-group randomized clinical trial conducted across 15 academic trauma centers in the United States between 2016 and 2022.

• Study Participants: The trial enrolled 524 adult trauma patients who were ventilated for less than 24 hours, had at least one risk factor for Acute Respiratory Distress Syndrome (ARDS), and were expected to remain on a ventilator for at least 24 hours.
• The Intervention: The intervention group (261 patients) received a sigh breath once every six minutes. The sigh was designed to produce a plateau pressure of 35 cm H2O (or 40 cm H2O for patients with a BMI greater than 35). The control group (263 patients) received usual care.
• Primary Outcome (Ventilator-Free Days): There was no statistically significant difference in the primary endpoint. The sigh group had a median of 18.4 ventilator-free days compared to 16.1 days in the usual care group (p=0.08).

Secondary Findings and Safety

While the primary endpoint was not met, several secondary outcomes favored the intervention:

• 28-Day Mortality: The sigh group showed a lower mortality rate (11.6%) compared to the usual care group (17.6%) with a p-value of 0.05.
• Extubation Time: Patients in the sigh group experienced a shorter time to successful extubation.
• Adverse Events: There were no significant differences in complications or nonfatal adverse events between the two groups, suggesting that sigh breaths are well-tolerated and not harmful.

The study concludes that while sigh breaths did not significantly increase ventilator-free days, they appear safe and may improve survival in trauma patients at risk for ARDS.

--------------------------------------------------------------------------------

Section 3: Cessation of Proton Pump Inhibitors (PPIs)

The Issue of Overprescribing

Proton pump inhibitors (PPIs) are commonly initiated in the ICU for stress ulcer prophylaxis. While the recommended duration is typically eight weeks, these medications are frequently continued indefinitely without a clear medical indication after hospital discharge. This lack of timely cessation imposes an economic burden and significant health risks.

The Palmowski et al. Study (2024)

This nationwide retrospective cohort study utilized health claims data from a large German insurer, covering 591,207 hospitalized patients, to examine the impact of unnecessary PPI continuation.

• Study Scale: Researchers identified 11,576 ICU patients who were prescribed PPIs for the first time during their stay without an indication for long-term use.
• Prevalence of Overtreatment: Approximately 41.7% (4,825 patients) continued PPI therapy beyond eight weeks post-discharge without an objectifiable indication. Nearly half of these patients remained on the therapy for more than a year.

Clinical Consequences of Unnecessary PPI Use

The study identified several significant risks associated with the unnecessary continuation of PPIs:

• Infections and Organ Health: A 27% increased risk of pneumonia and a 26% increased risk of chronic renal failure.
• Cardiovascular Events: A 17% increased risk of cardiovascular events.
• Malabsorption and Nutritional Deficiencies: Increased risks for Vitamin B12 deficiency (1.3 fold), hypomagnesemia (2.1 fold), and hypocalcemia (1.6 fold).
• Neoplasms: A 2.7 fold increased risk of esophageal cancer and a 2.4 fold increased risk of pancreatic cancer.
• Healthcare Utilization and Mortality: Continued PPI therapy was associated with a 34% greater risk of rehospitalization and a nearly 20% higher 2-year mortality risk (Hazard Ratio 1.17).

The researchers emphasized that ICU physicians must remain vigilant and ensure the timely cessation of PPI therapy to prevent these avoidable clinical consequences.

--------------------------------------------------------------------------------

Glossary of Key Terms

• Acute Respiratory Distress Syndrome (ARDS): A type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs.
• Angiotensin II (AT2/ATII): A potent vasoconstrictor used to increase blood pressure in patients with refractory shock.
• ATHOS-3: A prominent clinical trial that investigated the efficacy of Angiotensin II in treating vasodilatory shock.
• Distributive Shock: A medical condition where abnormal distribution of blood flow results in inadequate supply to the tissues.
• Hazard Ratio (HR): A measure of how often a particular event happens in one group compared to another over time.
• Mean Arterial Pressure (MAP): The average arterial blood pressure during a single cardiac cycle; used as an indicator of perfusion to vital organs.
• Odds Ratio (OR): A statistic that quantifies the strength of the association between two events or characteristics.
• Plateau Pressure: The pressure applied to small airways and alveoli during mechanical ventilation.
• Pragmatic Trial: A clinical trial designed to test the effectiveness of an intervention in real-life routine practice conditions.
• Propensity Score Matching: A statistical technique used to estimate the effect of an intervention by accounting for the covariates that predict receiving the treatment.
• Proton Pump Inhibitors (PPIs): Medications used to reduce stomach acid production, often used in ICUs for stress ulcer prophylaxis.
• Refractory Shock: Shock that does not respond to standard treatments, such as fluid resuscitation and initial vasopressor therapy.
• Sequential Organ Failure Assessment (SOFA) Score: A scoring system used to track a person's status during the stay in an ICU to determine the extent of a person's organ function or rate of failure.
• Stress Ulcer Prophylaxis: Medical treatment intended to prevent the formation of ulcers in the gastrointestinal tract during periods of severe physiological stress, such as critical illness.
• Surfactant: A fluid secreted by the cells of the alveoli that reduces surface tension, preventing lung collapse.
• Tidal Volume: The amount of air that moves in or out of the lungs with each respiratory cycle.
• Vasodilation: The widening of blood vessels, which leads to a decrease in blood pressure.
• Ventilator-Induced Lung Injury (VILI): Lung damage caused by mechanical ventilation.